Atrial Fibrillation Clinical Trials in Indianapolis, Indiana

6 studies are recruiting for atrial fibrillation in Indianapolis, Indiana right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Fourth Left Atrial Appendage Occlusion Study

   LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Community Health Network Inc., Indianapolis, Indiana

   Locations

   150 in total

   Run by

   Hamilton Health Sciences Corporation

   See if you can join NCT05963698 on ClinicalTrials.gov

2. The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

   REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in parti…

   Stage

   Phase 3

   Ages

   22 to 85

   Site

   Ascension St. Vincent, Indianapolis, Indiana

   Locations

   93 in total

   Run by

   Johns Hopkins University

   See if you can join NCT05836987 on ClinicalTrials.gov

3. Tracking Results of Ablations to Combat AF Registry Generation 2

   The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac ablation.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Franciscan Health, Indianapolis, Indiana

   Locations

   29 in total

   Run by

   AtriCure, Inc.

   See if you can join NCT05111015 on ClinicalTrials.gov

4. Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

   The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated c…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Indiana University, Indianapolis, Indiana

   Locations

   106 in total

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT04045665 on ClinicalTrials.gov

5. Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

   Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in b…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   IU Health Methodist Hospital, Indianapolis, Indiana

   Locations

   187 in total

   Run by

   Yale University

   See if you can join NCT03907046 on ClinicalTrials.gov

6. Ondansetron for the Management of Atrial Fibrillation

   "Afib" is a common irregular heartbeat. Afib can cause stroke, blood clots, dementia and death. Medicines used to treat Afib often do not work well and can cause serious side effects. Clinicians need medicines that work better for Afib. Medicines for Afib work by blocking a current in the heart cal…

   Stage

   Phase 4

   Ages

   18 to 100

   Site

   Indiana Clinical Research Center, Indianapolis, Indiana

   Locations

   3 in total

   Run by

   Indiana University

   See if you can join NCT05844501 on ClinicalTrials.gov